As the global biopharmaceutical industry undergoes rapid transformation, Southeast Asia, with its burgeoning market potential and demand for industrial upgrades, has become a new hotspot for international pharmaceutical competition and collaboration.

As a major annual event for the pharmaceutical industry in Southeast Asia, CPHI South East Asia 2025 is not only a platform for showcasing technological achievements but also a bridge for the deep integration of pharmaceutical resources. Tailin, a leading enterprise in China’s pharmaceutical equipment sector, participated with cutting-edge solutions, signaling a strong step toward deeper synergy with the Southeast Asian pharmaceutical industry.

At this exhibition, Tailin showcased key solutions spanning the entire biopharmaceutical production process, forming a multi-dimensional and systematic product matrix. The exhibited products cover core areas including aseptic production, leak testing, microbial detection, and water quality safety testing. These offerings respond precisely to the real needs of the Southeast Asian market in terms of GMP compliance upgrades and production capacity optimization, demonstrating Tailin’s professional strength and comprehensive service capabilities in helping customers improve production efficiency and quality control.

Tailin’s participation in CPHI SEA 2025 marks a key milestone in advancing its globalization strategy. As a pioneering enterprise driving China’s pharmaceutical equipment industry onto the international stage, Tailin is building a comprehensive and multi-layered cooperation network in the Southeast Asian market through technical collaboration, capacity coordination, and ecosystem co-construction.

More info: CPHI South East Asia 2025 | YouTube